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PRACTICAL MANAGEMENT
OF THERAPEUTIC
DIPHENYLHYDANTOIN
CONCENTRATIONS IN CHILDREN
A Smit, JF Schoeman, H I Seifart, D P Parkin
Objective. Development of easy, practical methods for the
management and optimisation of therapeutic
diphenylhydantoin (DPH) concentrations in children.
Design. Investigation of DPH concentration profiles and
pharmacokinetic parameters in children with poorly
controlled epilepsy. Subsequent determination of
individual-specific DPH maintenance dosage and volume
of distribution data suitable for use in routine therapeutic
concentration management procedures.
Setting. Department of Paediatrics and Child Health and
Department of Pharmacology, University of Stellenbosch,
Tygerberg Hospital.
Subjects. Children of both sexes between the ages of 4 and
12 years with poorly controlled epilepsy receiving DPH as
sole medication.
Results. In all subjects evaluated epilepsy was
unsatisfactorily controlled because of inadequate DPH
dosage regimens. Individual-specific maintenance dosage
and volume of distribution data could be calculated for all
individuals participating in the trial. The calculated data
were· suitable for use in routine management procedures
and in no instance was it necessary to recalculate
parameters in a 12-month follow-up period subsequent to
evaluation.
Diphenylhydantion (DPH, phenytoin) is widely used in
paediatric patients for the treatment of generalised tonic/ clonic
seizures, tonic seizures, partial seizures, secondarily
generalised seizures and status epilepticus.14 Although DPH is
an excellent drug when indicated, less effective alternatives are
perhaps often used in preference because of the
pharmacokinetic difficulties generally encountered in
accurately controlling therapeutic concentrations in the
therapeutic range (10 - 20 mg/l).5
The rate of DPH elimination is governed by metabolic. ~.
processes that are saturated at relatively low concentrations
since the Michaelis constant is low (Km = 5.7 ± 2.9 mg/l in
adults") relative to optimal therapeutic steady-state
concentrations. Consequently, the rate conditions governing
DPH elimination change from essentially first-order in the
subtherapeutic range, to essentially zero-order in the
therapeutic and higher ranges. As indicated by the data in
Table I, derived from population parameters," the change is a
continuum.
Therapy with a drug such as DPH, which is subject to zero-
order elimination rate phenomena, is not easily controlled and
requires special techniques, since, in contrast to true first-order
rate processes, dosage and steady concentrations are not
linearly related; a modest increase in the maintenance dose
(MD) may cause an extensive increase in the steady-state
concentration; a maximal elimination rate exists and if a
maintenance dosage in excess of the maximum is administered,
concentrations will never stabilise but will increase
Table I. Derived data from population parameters for larger
children and adults in respect of DPH, assuming Vm = 9.22 mg/l/d;
Km =5.7 mgII and a Vd =O.64l/kg
[DPH] v=Ro k a t1/2 MD
(mg/l) (mg/l/d) (I/d) " (l/kg/d) (d) (mg/l/d)(mg/kg/d)
[DPHJ = diphenylliydantoin (DPH) steady-state concentration; v = Ko = elimination
velocity or rate oul; k = first-order elimination rate constant; 0 = clearance; tn =
elimination half-life; MD = maintenance dose.
A quick plot of the data will show that: (i) a maintenance dose equal to the
biotransformation or elimination rate (v) is not linearly related to the DPH steady
concentration that will ensue; (ii) the first-order"elimination rate constant (k. lId) and
clearance (0) = kVd.l/kg/d are not linearly related to [DPH); and (in) the elimination
or biotranslormation half-life, in contrast to k. is indeed linearly related'to [DPH).
Conclusions. Therapeutic DPH concentration profiles can be
managed satisfactorily in children if individual-specific
DPH pharmacokinetic parameters are derived and skilfully
applied. "
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continuously and inexorably to toxic levels; and the elimination
half-life is directly proportional to concentration and increases
as concentration increases. These aspects are well illustrated in
the data derived from population parameters' and are
indicated in Table I.
Although a number of methods have been devised to
optimise DPH maintenance dosage/·n they do not address the
practical, hands-on DPH dosage and concentration
management skills required for routine application in
environments with less sophisticated health care
infrastructures. The methods described here address these
issues and involve three clear objectives: (i) careful estimation
of the maximal elimination rate of DPH for the purpose of
calculating an appropriate daily maintenance dosage; (ii)
estimation of the volume of distribution for the purpose of
calculation of adjustment dosages that are inevitably required
from time to time; and (iii) adjustment measures, not involving
alterations to the maintenance dosage, for appropriate upward
or downward displacement of the DPH concentration-time
([DPH]-time) profile applicable to the dosage interval.
The methods presented here are an aid to, but do not replace,
the need for ongoing therapeutic concentration monitoring. It
is important that the clinician has a clear understanding of the
[DPH]-time profile that needs to be achieved, and how best to
achieve it.
METHODS
Patients
Ten children of both sexes between 4 and 12 years of age being
treated with DPH for seizure control, but in whom therapeutic
results were unsatisfactory, were admitted to the study
provided that they were receiving no medication other than
DPH. The demographic data are shown in Table IT. Approval
for the study was obtained from the Institutional Ethics
Authority and consent for inclusion of a child in the trial was
obtained from a parent or guardian.
Dosage and sampling
All the children had been treated with DPH for at least 2 weeks
before admission to hospital. DPH concentrations were
determined on admission to evaluate therapeutic drug level
status as a first step in determining the cause of unsatisfactory
seizure control. A single oral best-estimate DPH dose was then
administered by the attending paediatrician in an attempt to
elevate DPH concentrations to within the therapeutic range. On
the following day, the trial day, extending over 24 hours, a
baseline blood sample ([DPHlb) was drawn immediately before
the time of administration of an intravenous test dose of DPH
(approximately 5 mg/kg body weight) by slow bolus
intravenous injection, i.e. at a rate less than 0.75 mg/kg/min.12•14
Table II. DPH concentration versus time data following
administration of a test dose of DPH by slow IV injection
Patient Mass Age Dose [DPHlb [DPHl. [DPH1,.
No. (kg) (yrs) (mg/kg) (mg/l) (mg/l) (mg/l)
1 22..7 9 5.00 5.50 13.87 5.48
2 320 7 5.00 1.90 7.09 1.30
3 25.3 8 5.14 3.00 8.66 221
4 20.6 6 4.85 1.10 6.58 0.98
5 20.0 8 5.00 3.00 7.66 1.36
6 18.5 9 5.00 3.60 9.82 3.48
7 30.0 11 5.00 2.60 8.77 1.60
8 16.1 4 4.97 1.00 6.23 1.17
9 20.0 8 7.50 2.57 10.44 1.89
10 30.4 12 4.93 3.97 9.67 3.10
[DPH]" = the baseline DPH concentration immediately before adminisUation of the IV
test dose; [DPHl,. = the peak concentration measured at the interrept of the best-fit
linear concentration-time graph with the ordinate; [DPHI~= the concentration 24 hows
after completion of the administration of the test dose.
Blood samples (1 rnI) for the determination of DPH
concentrations were then drawn 6, 16 and 24 hours after
completion of the injection. In no instance had a patient
received DPH in the 12-hour period before the time the test
dose was given.
Analytical methods
Blood samples (1 rnI) were collected into 1.5 rnI Eppendorf
tubes and allowed to clot, after which they were centrifuged at
5000 g for 5 minutes to sediment fibrin in suspension. The
serum was then analysed in triplicate for DPH content using an
Abbott AXSYM Phenytoin IT System (Abbott Laboratories,
Diagnostic Division, USA), which is an immunoassay utilising
fluorescence polarisation technology.
Precision was determined as described in the National
Committee for Clinical Laboratory Standards (NCCLS)
protocol by the addition of known quantities of phenytoin to
recalcified drug-free plasma. The intra-run and inter-run
coefficients of variation at DPH concentrations of 7.5, 15.0 and
30.0 mg/l were 1.94, 2.07 and 2.46% and 3.94, 3.52 and 2.84%,
respectively. The coefficient of variation for DPH analyses in
our laboratory falls well within the specifications indicated by
the manufacturer.
Recovery of assay procedure was performed by comparison
of spiked plasma samples with spiked buffer samples. An
overall recovery rate of 99.88 ± 1.96% was found within the
concentration range of 2.5 - 20.0 mg/I. At concentrations of
below 0.5 mg/l both recovery and the coefficient of variation
were found to be outside the 95% confidence interval (Cl); the
sensitivity was therefore defined as 0.50 mg/l, representing the
lowest measurable concentration that can be distinguished
from zero with 95% confidence.
I •
Time (h)
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Table m. Pharmacokinetic parameters of trial subjects following
administration of an IV test dose of DPH
Patient Mass Vd v=Ro MD [DPHltroogh
No. (kg) (I/kg) (mg/l/h) (mg/kg/d) (mg/I/d) (mg/!)
1 22.7 0.597 0.350 5.02 8.40 10.80
2 32.0 0.963 0.241 5.57 5.78 12.11
3 25.3 0.908 0.270 5.88 6.48 11.76
4 20.6 0.885 0.233 4.95 5.59 12.21
5 20.0 1.073 0.263 6.77 6.31 11.85
6 18.5 0.804 0.265 5.11 6.36 11.82
7 30.0 0.810 0.298 5.79 7.15 11.43
8 16.1 0.950 0.211 4.81 5.06 12.47
9 20.0 0.953 0.357 8.17 8.57 10.72
10 30.4 0.865 0.278 5.77 6.67 11.67
Mean 0.8808 0.2766 5.7840 6.6370
(±SD) (0.1208) (0.0449) (0.%%) (1.0786)
Vd =apparent volume of distribution of OPH; v =Ro =OPH elimination velocity or
rate out; MD =OPH maintenance dose; [DPHl_ =optimal target trough OPH
ooncentration.
Trough concentration ([DPHl.oo.,J The optimal trough
concentration was calculated from the optimal therapeutic
concentration, set at 15 mg/I for larger children and adults,"
and the calculated MD expressed in terms of mg/I/ d, as
follows:
(DPH]troogh = (15 - (MD/2» mg/I (4)
Loading or adjustment dose (LO, AD). The most
appropriate loading or adjustment (upward) dose can be
calculated from the target (DPH]trough value and the measured
situational DPH trough concentration ([DPH]"""""",,), as !o]lows:
LD or AD = Vd «(DPHtrough - [DPH]=.......t)' mg "(5)
RESULTS
The baseline ([DPH]b)' peak ([DPH]p) and 24-hour post-dose
([DPH],.) concentrations of each individual, generated on the
trial day, are shown in Table n. The apparent volum~.of
distribution of DPH (Vd, I/kg), the apparent maximal DPH
elimination rate (v = Ro, mg/I/h), the optimal daily
maintenance dose, in both volume and mass terms (MD:
mg/kg/ d; mg/l/ d), and the optimal target trough
concentration ((DPH]troogh mg/I), were calculated for each of the
children. The results are shown in Table rn.
There was considerable inter-individual variation in our
.patients both in terms of the volume of distribution and the
required daily maintenance dosage, as was to be expected
among children of widely differing age, with means
(± standard deviations) of 0.88 (± 0.12) I/kg for Vd and 5.78
(± 0.97) mg/kg/ d for MD. The Vd of 0.88 (± 0.11) I/kg was
considerably higher than that reported for adults, i.e. 0.64
(± 0.04) l/kg,6 notwithstanding the fact that the Vd values were
not determined under proper steady-state conditions. On the
other hand, the mean (SD) of the required maintenance dosage
24
(1)
(3)
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MD = Ro x Vd x 1:, (mg/d)
Peak concentration. The peak concentration ([DPH]p)' at
time zero, was determined from the intercept of the [DPH]-
time graph and the ordinate.
Volume of distribution (Vd). The apparent Vd was
calculated from [DPH]", [DPH]p and the magnitude of the DPH
test dose (D), as follows:
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CALCULATIONS
Graphic representation of measured concentration versus
tUne data. Least squares linear regression was performed on
the plasma [DPH]-tirne data of each patient and the resulting
graph was back-extrapolated to time zero (t = 0). Tune zero,
indicating the origin of the ordinate, was taken as the time at
which the baseline sample ([DPH]b) was collected and the DPH
test dose was administered, in the same order, in rapid
succession.
Elimination rate or rate out (Ro, mg/l/h). Ro was calculated
directly from the slope of the best-fit linear graph of the [DPH]-
time data, as per Fig. 1.15 Ro was also calculated from the two
most distal [DPH]-tirne data points using the equation:
Ro =([DPH]ll - [DPH],,) / (t2 - t,) mg/I/h (2)
in which [DPH]u and [DPH]" are DPH concentrations
applicable to times t1 and t2 in the post-distribution phase.
DPH concentrations measured at 6 and 24 hours after the test
dose were used in the digital calculations.
Maintenance dose (MD, mg/d). The daily maintenance dose
was calculated as:
in which 1: is the dosage interval in hours, with 24 hours in the
trial.
Fig. 1. Origins ofconcentration factors requiredJor the
determination of the DPH elimination velocity or rate out (Ro = v,
mg/I/h) and volume ofdistribution (Vd, I). ([DPHl. = baseline
concentration; lDPHJp = post-dose peak concentration following an
IV test dose; SI' 5" S3 = sampling times.)
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Fig. 2. Hypothetical concentration-time profiles (trace A =
maintenance dose too low; trace B = maintenance dose optimal and
concentration-time profile optimally located within the therapeutic
range; trace C = maintenance dose correct but concentration-time
profile inappropriately high; trace D = maintenance dose too high).
50 ,---------------------,
phenomena on elimination rate (v) parameters. Once the daily
MD most appropriate to the individual has been determined,
the required total daily dosage may be subdivided, if necessary,
to accommodate the needs of a 12-hourly dosage regimen.
It is clear that a MD calculated from the slope of the best-fit
linear graph will approximate, but not overestimate, the
maximal permissible MD of DPH since the slope of the [DPH]-
time graph will approach, but never attain, a maximum; at
maximum slope the maximal elimination rate, i.e. the V~
component in Michaelis-Menten concepts, applies. Although
occasional minor upward displacement of [DPH]-time profiles,
by means of a single adjustment dose, was necessary in all our
patients in the 12-month post-trial follow-up period, in no
instance was the MD excessive, and consequently in no
instance did DPH concentrations show a tendency to rise
inexorably to toxic levels as shown hypothetically in trace D of
Fig. 2.
For the reasons discussed above, in the chronically
underdosed patient or the patient who has not previously
received but is now to be treated with DPH, an IV test dose for
the purpose of computation of specific pharmacokinetic
parameters is advisable in order to circumvent complications
related to the rate and / or extent of DPH absorption and
distribution.ls On the other hand, [DPH]-time data required for
the calculation of the DPH elimination rate can easily be
determined directly in the patient presenting with
DPH concentrations were subtherapeutic in all our children,
and in the final analysis poor seizure control could be ascribed
directly to inadequate dosage in all instances. The consistent
trend in the direction of subtherapeutic DPH concentrations
probably reflects awareness of the zero-order pharmacokinetic
profile of DPH concentrations in the therapeutic range and the
desire of the clinician not to overdose the patient.
For decades DPH pharmacokinetics have been used as a
model for the study of saturable in vivo xenobiotic elimination
phenomena. Useful data have been generated and a variety of
methods of varying degrees of sophistication have been
derived with which to maintain DPH concentrations within
therapeutic limits.'·n The unsophisticated but eminently
practical methods presented here have the advantage of being
intuitively easy to understand and, once learnt, extremely user-
friendly. They are also immediately applicable to any
circumstance at all stages of therapy; i.e. from initiation of a
DPH-eontaining regimen through to long-term maintenance
therapy, almost inevitably complicated from time to time by
aberrations in dosage, absorption or compliance.
As practical 'hands-on' skills develop, the careful clinician
with some experience should not find it difficult to manage
therapy involving DPH provided that high-quality DPH
analytical services are available for routine monitoring
purposes. In this regard a method for the quantitation of DPH
with an SD of less than 5% is required. A rapid specimen
delivery-analytical result turnaround time also does much to
facilitate efficient correction of aberrant [DPH]-time profiles.17
Since IV injection of DPH ensures absolute and immediate
bio-availability, the time to the linear elimination phase is
decreased considerably, allowing sufficient time within a 24-
hour dosage interval for the collection of the requisite well- and
widely-spaced samples. Consequently, it is practically easy to
estimate graphically, or to determine by least-squares linear
regression, the slope of the [DPH]-time graph from 3
appropriately spaced accurately measured [DPH]-time data
points within a 24-hour dosage interval. The elimination rate
(Ro, mg/l/h) calculated (as per equation 2) from [DPH]-time
data 6 and 24 hours after the test dose did not differ
significantly (data not shown) from the values calculated
directly from the best-fit linear graph.
Whenever possible the DPH elimination characteristics of the
individual should be determined over a 24-hour period in
order to minimise the impact of distribution/ redistribution
for our children, MD = 5.78 (± 0.97) mg/kg/ d, closely
approximated the elimination Vm data reported for adults, i.e.
Vm = 5.9 (± 1.2) mg/kg/ d. What our data do show is that
notwithstanding similarities, population data applicable to
adults are of only limited use in planning a dosage regimen for
an individual child.
DISCUSSION
Flowchart indicating procedures to be followed in the
management of aberrant therapeutic diphenylhydantoin
concentrations
If the therapeutic control of the patient being treated with DPH
for epilepsy is unsatisfactory, determine the trough [OPHj as a
priority in the initial clinical evaluation.
[DPHL mg/l = OPH concentration; N injection should proceed at a rate not
exreeding 0.75 mg/kglmin,.tt-W MD, mg/lld - calculate the maintenance dose using"
equation 3, consulting Fig. 1 and the text for clarification; ill or AD, mg - calculate
the most appropriate loading dose or adjustment dose using equation 5; use the
individual-specific volume of distribution. vide infra, if known, and population
parameters if no!; Vd, 1-calculate the volume of distribution using equation 1,
consulting Fig. 1 and the text for clarification; Trough concentration ([D!'HL.), mg/l
- calculate the most appropriate [DPHl. value using equation 4 and consulting
the text for clarification.
region; the location of the profile should be displaced
downward into the therapeutic range by withholding a DPH
dose, or fraction of a dose, as appropriate. Trace D: MD is in
excess of the maximal permissible MD (V~ in classic
Michaelis-Menten concepts) and the [DPH]-time data indicate
excessive and ever-increasing concentrations; DPH dosage
should be withheld until concentrations fall within the
therapeutic range, and an appropriate MD should be
determined directly from appropriately spaced [DPHj-tirne
data as concentrations decline.
If [OPHj is subtherapeutic
condition A in Fig. 2
applies.
1. If [DPH] is supratherapeutic,
either condition C or
condition D in Fig. 2 applies.
3. From the slope of the linear
graph of the [DPH]-time data
determine the correct MD.
2. Withhold therapy and repeat Administer a LD of DPH
[OPH] determinations 12- calculated to approach a
hourly until [DPHj approaches [OPB] of 20 mg/l by slow
10 mg/I. IV injection; effect [OPB]
determinations 12-hourly
until [DPH] approaches
lOmg/I.
From the slope of the linear
graph of the [OPH]-time
data determine the correct
MD and the Vd.
4. Having determined, or confirmed, the correct MD,
continue with maintenance therapy using the correct
MD after administering a LD/ AD to elevate trough
[OPHjs appropriately.
It is clear from Fig. 2 that allowance must be made for any
dose of DPH that the patient neglects to take or any additional
dose that the patient accidentally takes, by appropriately
adding a dose or withholding a dose as the situation demands.
An adjustment dose may be administered at any time but large
doses should be subdivided and administered at appropriate
intervals, e.g. the larger portion should be administerea at
bedtime. A constant and meticulous record of DPH dosage
should be kept in order to be able to balance dosage excesses
and deficits weekly. It should be borne in mind that if a patient
takes one MD extra, or neglects to take a single MD, he or she
will effectively be and remain overdosed or underdosed,
supratherapeutic concentrations by the simple expedient of
obtaining a set of samples over the time-course of the decline
of DPH to the lower range of therapeutic concentrations (10
mg/I). Each such untoward event should be utilised to
determine, confirm or improve information in respect of the
most appropriate maintenance dosage.
An additional advantage of an IV test dose of DPH is that it
allows approximation of the apparent Vd of the individual
from data generated, as described, by extrapolation of the
linear section of the [DPHj-time graph to the time of
completion of administration of the test dose, marked by the
location of the ordinate. The volume of distribution is required
for efficient upward or downward displacement of the
therapeutic [DPHj profiles since occasional one-off adjustments
should be seen as an integral part of DPH maintenance
concentration management. As shown in Table rn, at the outset
of therapy individuals may have a Vd that differs significantly
from, or which falls in the extremes of, the quoted range; these
individual-specific values should be taken into account
whenever adjustment procedures become necessary. As
therapeutic DPH steady-state concentrations are approached
and deep tissue compartments become saturated the apparent
Vd values tend, theoretically, to decrease to a stable minimum.
If Vd is not calculated, as is often not possible in routine
therapeutic monitoring situations, it should be estimated from
populations parameters, e.g.:
Vd = mass (kg) x 0.64 (l/kg) I, (6)
0.64 ± O.04I/kg being the mean population parameter for
children older than 12 years and adults (when concentrations
are within the therapeutic range and at steady state).
Population parameters for children vary considerably from
those of adults and true steady-state conditions rarely apply; in
difficult cases pro-active determination of the volume of
distribution by the methods described are justifiable.
The impact of variation of DPH elimination characteristics
from essentially first-order at lower concentrations to
essentially zero-order at therapeutic and higher concentrations
is shown graphically in sequence in Fig. 2. The usual
distortions to the essentially linear [DPHj-time graph, caused
by delays or lag-times in absorption and systemic distribution,
have been ignored for the purposes of simplicity since they are
essentially irrelevant in the therapeutic setting. The dosage-
dependent [DPHj-time profile can generally be described by
one of the four traces A to D constituting Fig. 2. Trace A: the
MD, and consequently the therapeutic [DPH]-time profile, are
~ too low; the correct MD should be determined and an
adjustment dose of appropriate magnitude should be given to
displace the [DPH]-time profile upwards into the therapeutic
range. Trace B: the MD is optimal and the therapeutic [DPHj-
time profile is satisfactorily located within the therapeutic
range; no intervention is necessary. Trace C: MD is optimal but
the [DPHj-time profile is located in the supratherapeutic
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respectively, until such time as appropriate adjustment is made.
A flowchart summarising the steps that should be followed
when managing aberrant DPH concentrations is shown in
orde: to fix concepts, as well as for convenience. It is helpful,
initially, to pay particular attention to the units being used in a
particular equation;·as familiarity with procedures develops
interconversion between units presents no real difficulties.
To obtain a true steady-state concentration in the therapeutic
range in a patient receiving treatment with oral DPH requires
'meticulous compliance with a precisely determined and correct
MD, constant absolute bio-availability characteristics of the
DPH formulation being administered and constant absorption
from the gut over a sufficiently long period of time. In the
practical therapeutic setting such a condition, not requiring
ongoing therapeutic monitoring, adjustment and correction, is
the very rare exception rather than the rule. The only workable
way in which to ensure acceptable, if not optimal, therapeutic
results in less sophisticated populations is to encourage full co-
operation between physician and patient in an attempt to
ensure compliance; use of high-quality DPH formulations; and
skilful application of adjustment and correction techniques
based on high-quality routinely generated analytical [DPH]
data.
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COMPLIANCE OF THE
RESPIRATORY SYSTEM AS A
PREDICTOR FOR SUCCESSFUL
EXTUBATION IN VERY-LOW-BIRTH-
WEIGHT INFANTS RECOVERING
FROM RESPIRATORY DISTRESS
SYNDROME
JSmith, C H Pieper, D Maree, R P Gie
Objective. To develop additional criteria to predict for
successful extubation of very-low-birth-weight infants
recovering from respiratory distress syn~ome.
D~ign.Prospectivesmd~
Setting. Neonatal intensive care unit at a university teaching
hospital.
Interventions. Infants ready for extubation according to
clinical, ventilatory and blood gas criteria were studied.
Before extubation, tidal volume (Vt), minute ventilation,
respiratory rate/Vt and mean inspiratory flow were
measured during two different ventilatory settings: (i) during
intermittent mandatory ventilation (IMV); and (ii) while
breathing spontaneously with endotracheal continuous .
positive airway pressure (CPAP). Tidal volume was obtained
through electronically integrated flow measured by a hot-
wire anemometer. Total respiratory compliance (Crs) was
determined during IMV and was derived from the formula
Vt/PIP-PEEP, where the difference between peak inspiratory
pressure (PIP) and positive end-expiratory pressure (PEEP)
represented the ventilator inflation pressure.
Measurements and main results. Each of 49 infants was studied
once before exmbation. 33 infants (67%) were successfully
exmbated and 16 (32.6%) required reintubation. Infants in the
success and failure groups were matched for gestation, post-
conceptional age, study weight and methylxanthine therapy
at the time of study. Successful extubation was associated
with a higher mean absolute Crs value (ml/cm H 20) specific
Crs value (standardised for body length; ml/ cm Hp/ cm)
compared with infants in whom extubation failed (0.67 v.
0.46; P = 0.01 and 0.018 v. 0.014;
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